An Onclive interview reveals the overall status of immunotherapy under investigation in myeloma including:

    • Checkpoint inhibitors
    • Antibody-drug conjugates (ADCs)
    • Bispecific T-cell engages (BiTEs)

In an interview during the 2018 OncLive® State of the Science Summit™ on Multiple Myeloma, which was held ahead of the 2018 ASH Annual Meeting, Hearn Jay Cho, MD, PhD, was interviewed to discuss the status of these investigational therapies.

Source: OncLive

Pin It on Pinterest